Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - dcxxxx
123
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Mononegavirales Vectors Expressing Chimeric Antigens
Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide, and also is an important cause of morbidity and mortality in the elderly. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use...
Published: 10/28/2024
|
Inventor(s):
Linda Brock
,
Ursula Buchholz
,
Peter Collins
,
Shirin Munir
Keywords(s):
Added
,
Attenuated
,
DA4BXX
,
DA4XXX
,
DC5BXX
,
DC5XXX
,
DCXXXX
,
DD1XXX
,
DDXXXX
,
DEXXXX
,
DXXXXX
,
Expressing
,
F
,
Fusion
,
Gene
,
Highly
,
Human
,
Immunogenic
,
Macaques
,
MPV
,
Murine
,
PNEUMONIA
,
Protein
,
respiratory
,
RHESUS
,
RSV
,
Syncytial
,
virus
Category(s):
Collaboration Sought > Collaboration
,
Application > Research Materials
,
Application > Diagnostics
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease
Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use
Vaccines for SARS-CoV-2 are increasingly available under emergency use authorizations; however, indications are currently limited to individuals twelve (12) years or older. They also involve intramuscular immunization, which does not directly stimulate local immunity in the respiratory tract, the primary site of SARS-CoV-2 infection, shedding and spread....
Published: 10/28/2024
|
Inventor(s):
Shirin Munir
,
Cindy Luongo
,
Peter Collins
,
Cyril Le Nouen
,
Xueqiao Liu
,
Ursula Buchholz
Keywords(s):
2
,
ACUTE
,
Attenuated
,
B/HPIV3
,
BOVINE/HUMAN
,
chimeric
,
CORONAVIRUS
,
DC5BXX
,
DC5XXX
,
DCXXXX
,
DDXXXX
,
DEXXXX
,
DXXXXX
,
Expression
,
GLYCOPROTEIN
,
PIV3
,
respiratory
,
S
,
SARS-CoV-2
,
SEVERE
,
spike
,
Syndrome
Category(s):
Collaboration Sought > Collaboration
,
TherapeuticArea > Infectious Disease
,
Application > Vaccines
,
Application > Research Materials
Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene
RSV is the most important viral agent of severe respiratory disease in infants and young children worldwide and also causes substantial morbidity and mortality in older adults. RSV is estimated to cause more than 33 million lower respiratory tract illnesses, three million hospitalizations, and nearly 200,000 childhood deaths worldwide annually, with...
Published: 10/28/2024
|
Inventor(s):
Cyril Le Nouen
,
Ursula Buchholz
,
Peter Collins
Keywords(s):
ADDITIONAL
,
BEARING
,
Codonpair
,
DA4BXX
,
DA4XXX
,
DAXXXX
,
DC5BXX
,
DC5XXX
,
DCXXXX
,
DDXXXX
,
Deoptimized
,
DXXXXX
,
GENES
,
Improved
,
Live-Attenuated
,
M
,
Mutations
,
N
,
NS1
,
NS2
,
P
,
Pgene
,
POINT
,
respiratory
,
RSV
,
SH
,
Syncytial
,
Vaccine
,
virus
Category(s):
Collaboration Sought > Collaboration
,
Application > Research Materials
,
Application > Diagnostics
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease
Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection of B Cells
Epstein-Barr virus (EBV) is the most common cause of infectious mononucleosis and is associated with nearly 200,000 cancers and 140,000 deaths each year. EBV-associated cancers include Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt B cell lymphoma, and EBV post-transplant lymphoproliferative disease. The latent reservoir for EBV in the body is...
Published: 10/28/2024
|
Inventor(s):
Wei Bu
,
Nathan Board
,
Kennichl Dowdell
,
Jeffrey Cohen
Keywords(s):
ANTIBODY
,
B
,
BLOCKS
,
Cells
,
DAXXXX
,
DB4BXX
,
DB4XXX
,
DB5XXX
,
DBXXXX
,
DC1XXX
,
DCXXXX
,
DDXXXX
,
DXXXXX
,
EPSTEIN-BARR
,
Fusion
,
Infection
,
Neutralizes
,
That
,
virus
Category(s):
Collaboration Sought > Collaboration
,
Application > Diagnostics
,
Application > Research Materials
,
Application > Vaccines
,
Application > Therapeutics
,
TherapeuticArea > Infectious Disease
Therapeutic and Diagnostic Targets for Severe RSV Infection
Respiratory Syncytial Virus (RSV) infects nearly all children by their second birthday. RSV usually causes mild respiratory illness, however, a subset of patients experience severe infection that require hospitalization. Successful host defense against viral pathogens requires rapid recognition of the virus and activation of both innate and adaptive...
Published: 10/28/2024
|
Inventor(s):
Daniel Menendez Rendon
,
Steven Kleeberger
,
Michael Resnick
Keywords(s):
DAXXXX
,
DBXXXX
,
DCXXXX
,
Human
,
Identifies
,
Infection
,
p53
,
PROMOTER
,
RESPONSIVE
,
Risk
,
RSV
,
Serious
,
SNP
,
TLR8
Category(s):
Collaboration Sought > Licensing
,
Application > Diagnostics
,
Application > Therapeutics
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease
Mononegavirales Vectors expressing Chimeric Antigens
Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV), a virus to which humans normally are not...
Published: 10/28/2024
|
Inventor(s):
Peter Collins
,
Ursula Buchholz
,
Linda Brock
,
Shirin Munir
Keywords(s):
Added
,
Attenuated
,
DA4BXX
,
DA4XXX
,
DC5BXX
,
DC5XXX
,
DCXXXX
,
DD1XXX
,
DDXXXX
,
DEXXXX
,
DXXXXX
,
Expressing
,
F
,
Fusion
,
Gene
,
Highly
,
Human
,
Immunogenic
,
Macaques
,
MPV
,
Murine
,
PNEUMONIA
,
Protein
,
respiratory
,
RHESUS
,
RSV
,
Syncytial
,
virus
Category(s):
Collaboration Sought > Collaboration
,
Application > Diagnostics
,
Application > Research Materials
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease
A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines
Rotavirus is a highly contagious, diarrhea-inducing pathogen that annually causes approximately 250,000 deaths worldwide and millions of hospitalizations, especially afflicting infants and young children. One strategy to combat this virus is through vaccination. Continuing safety and efficacy concerns with the currently existing live, oral vaccines...
Published: 10/28/2024
|
Inventor(s):
Roger Glass
,
Jean-Francois Saluzzo
,
Baoming Jiang
Keywords(s):
CDC Docket Import
,
CDC Docket Import CDC Prosecuting
,
DB4BXX
,
DB4XXX
,
DBXXXX
,
DC1XXX
,
DC5BXX
,
DC5XXX
,
DCXXXX
,
DXXXXX
,
Inactivation
,
Listed LPM Surabian as of 4/15/2015
,
NCIRD
,
OID-NCIRD-DVD
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
rotavirus
,
thermal
Category(s):
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease
,
Application > Therapeutics
Chlamydial Vaccine Technologies
The National Institute of Allergy and Infectious Diseases has invented three chlamydial vaccine technologies, which have shown promising preclinical efficacy. Chlamydia trachomatis infection is the most common sexually transmitted bacterial infection. If left untreated, chlamydia infection can lead to pelvic inflammatory disease and infertility. Chlamydia...
Published: 10/28/2024
|
Inventor(s):
Laszlo Kari
,
Deborah Crane
,
Harlan Caldwell
Keywords(s):
Against
,
Attenuated
,
-Attenuated
,
Bacterial strains
,
Blinding
,
Chlamydia
,
DA3XXX
,
DC4XXX
,
DCXXXX
,
DD1XXX
,
DDXXXX
,
DISEASES
,
Human
,
Immunogenic
,
Listed LPM Stansberry as of 4/15/2015
,
Live
,
Model
,
MULTIPLE
,
NON
,
Patent Category - Biotechnology
,
Plasmid-deficient
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
primate
,
Protective
,
RM
,
SAFE
,
Sexually
,
Strain
,
Trachoma
,
TRACHOMATIS
,
Transmitted
,
UBXXXX
,
Vaccine
,
VJXXXX
,
WIXXXX
,
WNXXXX
Category(s):
Collaboration Sought > Licensing
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
,
TherapeuticArea > Rare / Neglected Diseases
,
Application > Diagnostics
Neutralizing Antibodies to Influenza HA and Their Use and Identification
The effectiveness of current influenza vaccines varies by strain and season, in part because influenza viruses continuously evolve to evade human immune responses. While the majority of seasonal influenza infections cause relatively mild symptoms, each year influenza virus infections result in over 500,000 hospitalizations in the United States and Europe....
Published: 10/28/2024
|
Inventor(s):
Robert Bailer
,
Michael Joyce
,
John Mascola
,
Peter Kwong
,
Sarah Andrews
,
Paul Thomas
,
Gwo-Yu Chuang
,
Adam Wheatley
,
Yi Zhang
,
James Whittle
,
Adrian McDermott
Keywords(s):
1
,
2
,
antibodies
,
DB4XXX
,
DBXXXX
,
DC5XXX
,
DCXXXX
,
DXXXXX
,
GROUP
,
INFLUENZA
,
Neutralize
,
That
,
Their
,
Viruses
,
VLXXXX
,
WJXXXX
,
WNXXXX
,
XAXXXX
,
XKXXXX
,
YCXXXX
Category(s):
Collaboration Sought > Licensing
,
Application > Therapeutics
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease
,
ResearchProducts > Antibodies
,
TherapeuticArea > Immunology
Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2
Herpes simplex viral infections, including herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), are exceptionally common worldwide. These viruses establish lifelong persistent infections with cycles of lytic reactivation to produce recurrent diseases including oral and genital lesions, herpetic keratitis/blindness, congenital-developmental syndromes,...
Published: 10/28/2024
|
Inventor(s):
Jesse Arbuckle
,
Thomas Kristie
Keywords(s):
DB4BXX
,
DB4XXX
,
DBXXXX
,
DC5BXX
,
DC5XXX
,
DCXXXX
,
DEXXXX
,
DXXXXX
,
EZH1/2
,
HERPESVIRUS
,
Infection
,
Inhibitors
,
Latency
,
Listed LPM Fenn as of 4/15/2015
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
Reactivation
,
Suppresses
,
VLXXXX
,
WKXXXX
,
WNXXXX
,
XKXXXX
,
YBXXXX
,
YCXXXX
Category(s):
Collaboration Sought > Licensing
,
Application > Therapeutics
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease
1
2
3
4
5
6
7
8
9
10
...